Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Buy" by Analysts

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) have earned an average rating of "Buy" from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Thirteen investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $63.00.

Several research firms have commented on BHVN. Robert W. Baird increased their price objective on shares of Biohaven from $58.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, September 23rd. JPMorgan Chase & Co. raised their price target on Biohaven from $55.00 to $68.00 and gave the company an "overweight" rating in a report on Thursday, October 3rd. HC Wainwright reaffirmed a "buy" rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday, December 17th. Bank of America raised their target price on shares of Biohaven from $52.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th.

Insider Buying and Selling

In related news, Director John W. Childs bought 29,000 shares of the stock in a transaction dated Monday, December 30th. The stock was purchased at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now owns 2,368,741 shares of the company's stock, valued at $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 16.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biohaven

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Biohaven during the third quarter valued at $50,000. Values First Advisors Inc. bought a new position in Biohaven during the 3rd quarter worth about $78,000. US Bancorp DE increased its position in Biohaven by 57.1% during the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company's stock valued at $109,000 after purchasing an additional 790 shares during the period. KBC Group NV raised its holdings in shares of Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company's stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in shares of Biohaven by 19.1% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company's stock worth $156,000 after purchasing an additional 500 shares during the period. Institutional investors own 88.78% of the company's stock.

Biohaven Stock Up 4.0 %

NYSE BHVN traded up $1.50 during trading hours on Tuesday, reaching $39.09. The company's stock had a trading volume of 504,486 shares, compared to its average volume of 1,074,382. Biohaven has a 1 year low of $26.80 and a 1 year high of $62.21. The company has a market capitalization of $3.95 billion, a price-to-earnings ratio of -4.18 and a beta of 1.29. The firm's 50-day moving average price is $41.03 and its 200-day moving average price is $42.40.

Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Equities research analysts anticipate that Biohaven will post -8.85 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.